Abstract 97P
Background
In the global LEAP-017 trial, treatment with lenvatinib + pembrolizumab (L + P) trended toward longer, but not significant, OS (HR: 0.83, 95% CI: 0.68-1.02, p-value: 0.0379) vs regorafenib or trifluridine–tipiracil (SOC), and toward more benefit in PFS and ORR. We present results of an exploratory analysis of patients (pts) enrolled in Asia combined with an extension cohort from China.
Methods
Eligible pts were aged ≥ 18 years, with confirmed unresectable, non-MSI-H/dMMR mCRC, and ≥1 prior line of therapy. Pts were allocated (1:1) to L (20 mg QD) + P (400 mg Q6W, up to 18 cycles) or SOC. Primary endpoint was OS. Secondary endpoints were PFS and ORR per RECIST 1.1 by BICR, and safety.
Results
At data cut-off (Feb 20, 2023), 237 pts were enrolled from Asia including China (N=100), Japan (N=63), Korea (N=41), and Taiwan (N=33). Overall, 118 pts received L + P, and 117 received SOC. In the Asia subgroup, after a median follow-up of 15.1 months (mo) and 15.2 mo, respectively, OS was longer with L + P vs SOC (median 13.4 vs 10.3 mo; HR: 0.63, 95% CI: 0.45-0.88), median PFS was 3.8 mo with L + P and 3.3 mo with SOC (HR: 0.78, 95% CI, 0.58-1.05), and ORR was 11.9% (95% CI, 6.6%- 19.1%) with L + P and 0% with SOC. In the China cohort, OS was longer with L + P vs SOC (median 14.9 vs 10.3 mo; HR: 0.61, 95% CI, 0.33-1.15), median PFS was 3.7 mo with L + P and 2.4 mo with SOC (HR: 1.18, 95% CI, 0.75-1.85), and ORR was 5.7% (95% CI, 1.2%-15.7%) with L + P and 0% with SOC. Grade ≥ 3 treatment-related AE rates were 58.5% and 49.6% with L + P and SOC, respectively, in the Asia subgroup, and 43.9% and 64.3%, respectively, in the Chinese extension cohort. One grade 5 treatment-related AE of pneumonitis occurred in the L + P arm in the Asia subgroup.
Conclusions
In this exploratory analysis from the Asia subgroup of LEAP-017 including the China extension, treatment with L + P vs SOC trended toward longer OS, consistent with the global trial. Trends towards improved PFS and ORR with L + P were also seen, consistent with the global trial; however, a similar trend in the PFS HR in the China subgroup was not observed. No new safety signals were observed.
Clinical trial identification
NCT04776148; first posted on February 26, 2021.
Editorial acknowledgement
Provided by Jose Casasvonas Nieves, PhD, an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. H. Teng: Financial Interests, Personal, Advisory Role: MSD Taiwan; Financial Interests, Personal, Speaker’s Bureau: MSD Taiwan. A. Takashima: Financial Interests, Institutional, Research Funding: MSD. T. Yang: Financial Interests, Institutional, Research Funding: MSD. T.W. Kim: Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Funding: Merck. T. Kim: Financial Interests, Personal, Ownership Interest: IMBdx; Financial Interests, Institutional, Research Funding: MSD. J.O. Park: Financial Interests, Personal, Advisory Board: MedPacto, BMS (Celgene), Servier, MediRama, Adicet Bio, AstraZeneca, Merck Sereno, ImmuneOncia, Merck; Financial Interests, Personal, Other, Travel support for a poster presentation at ASCO GI 2023: Minneamrita Therapeutics LLC; Financial Interests, Personal, Research Grant, Clinical research grant: MedPacto, Servier, BMS (Celgene); Financial Interests, Personal, Research Grant: Eutilex, ABL Bio. S. Lee: Financial Interests, Institutional, Research Funding: MSD. K. Yeh: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, PhytoHealth, Novartis, Ono, Merck, AstraZeneca; Non-Financial Interests, Personal, Member: American Society of Clinical Oncology, American Association for Cancer Research. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd, Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd. R. Fu, R. Jain, D.E. Adelberg: Financial Interests, Personal, Full or part-time Employment: Merck. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks, Merck & Co.; Financial Interests, Personal, Invited Speaker: Taiho, Daiichi Sankyo, Eli Lilly, Bristol Myers Squibb, Ono, All other authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract